Research Paper
Examining the relationship between medical cannabis laws and cardiovascular deaths in the US

https://doi.org/10.1016/j.drugpo.2017.11.022Get rights and content

Abstract

Background

Several countries and many U.S. states have allowed, for cannabis to be used as therapy to treat chronic conditions or pain., This has increased the use of cannabis, particularly among older people.Because cannabis has been linked to adverse cardiac events in the medical literature, there may be unintended consequences on increased use among older people.

Methods

We analyze cardiac-related mortality data from the U.S. National Vital Statistics System for 1990–2014. We use difference-in-difference fixed-effects models to assess whether there are increased rates of cardiac-related mortality following passage of medical cannabis programs. We also analyze whether states with more liberal rules on dispensing cannabis show higher mortality rates.

Results

For men, there is a statistically significant 2.3% increase in the rate of cardiac death following passage. For women, there is a 1.3% increase that is also statistically significant. he effects increase or both men and women with age. The effects are also stronger in states with more a lax approach to cannabis dispensing.

Conclusion

Policymakers should be aware of a potential unintended consequence of allowing broader use of cannabis, specifically for those more at risk of cardiovascular events.

Introduction

The use of cannabis as therapy to treat chronic conditions or pain is now legal in a number of countries, with some nations, like Canada, providing such therapy through state-sponsored programs (Hazekamp and Heerdink, 2013, Hill, 2015).1 In the United States, there are 26 states and the District of Columbia that allowed for at least some use of cannabis as therapy be the end of 2016. Well over half of the U.S. population lives in those states.2 Other countries are currently debating whether allowing cannabis for medicinal use is appropriate. The UK recently reclassified cannabis extract as a medicine, which some think reopens serious discussion of allowing cannabis itself to be prescribed medically.3

We are interested in whether cannabis use, legal or illegal, is associated with cardiac-related mortality following the passage of state medical cannabis legalization (MCL) programs, which is the moniker for allowing cannabis for therapeutic purposes in the U.S. The association between cannabis and cardiovascular health has been documented for decades (Beaconsfield, Ginsburg, & Rainsbury, 1972; Charles, Holt, & Kirkham, 1979; Collins, Higginson, Boyle, & Webb, 1985; Fant, Heishman, Bunker, & Pickworth, 1998; Bachs and Mørland, 2001, Sidney, 2002) and is receiving renewed attention now that cannabis use is becoming even more common (Franz and Frishman, 2016, Singh et al., 2016). In population-based studies, the evidence is not conclusive (Frost, Mostofsky, Rosenbloom, Mukamal, & Mittleman, 2013; Jouanjus, Raymond, Lapeyre-Mestre, & Wolff, 2017). In one recent detailed study, Reis et al. (2017) followed a cohort of young men from young adulthood to middle age. No evidence of an association between cumulative and recent cannabis use was found.

MCL, however, might increase use among groups that would be more likely to be at risk for such an adverse cardiac event—specifically, those of advanced age. Using the National Survey on Drug Use and Health, Azofeifa (2016) documents a 333% increase in cannabis use rates among those age 65 and above and a 455% increase for those between ages 55 and 65. Conversely, overall growth in cannabis use was only 35% or about one-tenth of that for older people. There is also ample evidence that older adults are behaving in a fashion consistent with heightened medical cannabis use. Overall, new studies suggest that the Medicare enrollees are sensitive to cannabis and opioid drug policies. Bradford and Bradford (2016) show that spending on prescription drugs as part of Medicare Part D was significantly less in states that allowed for use of cannabis treat symptoms. The spending reduction was concentrated on medicines for which cannabis would be considered a viable alternative. Further suggestive evidence is provided by Nicholas and Maclean (2016) who use the Health and Retirement Study to identify that MCL increases labor supply among older adults, as well as some evidence of general health benefits, although they do not address death from cardiac events. These findings are all dependent on a heightened number of additional users of advanced age, which certainly appears to be the case. The primary drivers for such a change in use among older people over the past decade are cannabis legalization and a more general acceptance in the population of cannabis. The latter of course is a confounding factor in any study of the effects of medical cannabis. We suspect the surge has more to do with MCL, however, as Martins et al. (2016) confirms that the relative surge in use is concentrated among older individuals in MCL states.

Section snippets

Data

We use mortality data from National Vital Statistics System through the National Center for Health Statistics for 1990–2014 period to identify the number of deaths due to cardiovascular diseases in each state in each year. This dataset includes all deaths that occurred in the United States with information about socioeconomic background, including age at death, sex, the state of residence, and the cause of death for each individual. This allows us to separate deaths by age and sex as well. The

Statistical approach

We employ a standard difference-in-difference research design to assess the impact of MCL on cardiac mortality, similar to that used by Anderson, Rees, and Sabia, 2014.5 Specifically, we estimate the following regression:CVD ratest = α + β1MCLst+ Xstβ2 + δs + τt + Ttsst.

In model (1), the dependent variable is the number of cardiovascular deaths per 100,000 people in a particular sex-age group. MCLst is the policy variable,

Results

Table 2 provides descriptive statistics, first for the overall sample that includes both states passing MCL and those not. There were 303.753 cardiac-related deaths per 100,000 males per state-year over the 1990–2014 time period and 313.713 per 100,000 females. Cardiac deaths among those under 45 are comparatively rare. For the 45–64 age group, there is dramatic increase in heart deaths among both sexes, but males have approximately double the rate as females. Males and females age 65 and older

Discussion

We are the first to study whether the increased use of cannabis following its legalization for medicinal purposes is associated with cardiac health. Our study finds evidence suggesting that MCL was followed by increased cardiac mortality in states passing such laws compared with those that do not. This effect was concentrated among older individuals, particularly males, and states where there are less restrictions on dispenseries and cardholders. This effect is likely driven by increased

Conflict of interest

We received no funding for this project and therefore have nothing to declare in terms of conflict of interest.

References (36)

  • D.M. Anderson et al.

    Medical marijuana laws, traffic fatalities, and alcohol consumption

    Journal of Law and Economics

    (2013)
  • D.M. Anderson et al.

    Medical marijuana laws and suicides by gender and age

    American Journal of Public Health

    (2014)
  • A. Azofeifa

    National estimates of marijuana use and related indicatorsnational survey on drug use and health, united states, 2002–2014

    Morbidity and Mortality Weekly Report

    (2016)
  • M.A. Bachhuber et al.

    Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010

    JAMA Internal Medicine

    (2014)
  • P. Beaconsfield et al.

    Marihuana smoking: Cardiovascular effects in man and possible mechanisms

    New England Journal of Medicine

    (1972)
  • M. Bertrand et al.

    How much should we trust differences-in-differences estimates?

    The Quarterly Journal of Economics

    (2004)
  • A.C. Bradford et al.

    Medical marijuana laws reduce prescription medication use in Medicare Part D

    Health Affairs

    (2016)
  • R. Charles et al.

    Myocardial infarction and marijuana

    Clinical Toxicology

    (1979)
  • Cited by (29)

    • Marijuana legalization and opioid deaths

      2023, Journal of Health Economics
    • Cardiovascular effects of marijuana

      2019, Trends in Cardiovascular Medicine
      Citation Excerpt :

      Thus, marijuana use was associated with ventricular arrhythmias, sustained, and non-sustained ventricular tachycardia; it may even be linked to sudden death. Data from the United States National Vital Statistics between the years 1990–2014 were analyzed [15]. Cardiovascular-related mortality rates in states with liberal rules for dispensing marijuana were compared with other states.

    • Complete Heart Block From Chronic Marijuana Use

      2019, American Journal of the Medical Sciences
      Citation Excerpt :

      They found a statistically significant 2.3% increase in the rate of cardiac death following passage of medical cannabis programs in men and a 1.3% increase in women (also statistically significant). The rates were higher in states with a laxer approach to cannabis dispensing.14 Despite widespread belief of safety of marijuana, there is a growing body of evidence that these agents cause serious cardiovascular events.

    View all citing articles on Scopus
    View full text